Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6740201 | 0.88 | TP53 (0.44) | MAPTTP53SMN1; SMN2 | |
| SCHEMBL6740027 | 0.86 | MAPT (0.43) | MAPTTP53SMN1; SMN2GAA | |
| SCHEMBL6738536 | 0.75 | MAPT (0.37) | MAPTTP53SMN1; SMN2GAA | |
| SCHEMBL6818786 | 0.70 | STK4 (0.42) | — | |
| SCHEMBL7027867 | 0.70 | ERBB2 (0.40) | CNR2CNR1 | |
| SCHEMBL7032829 | 0.70 | — | — | |
| SCHEMBL7029061 | 0.69 | ERBB2 (0.40) | CNR2CNR1 | |
| SCHEMBL7035445 | 0.69 | ERBB2 (0.40) | CNR2CNR1 | |
| SCHEMBL7037054 | 0.69 | — | — | |
| SCHEMBL7031214 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023965-A1 | Imidazo-triazines as corticotropin releasing factor antagonists | GILLIGAN PAUL JOSEPH (US) | 2004-02-05 | — | — | US | disclosed |
| US-6579876-B2 | Imidazo(4,5-d)pyridazines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-06-17 | — | — | US | disclosed |
| US-20030055059-A1 | For therapy of psychiatric disorders and neurological diseases including affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease | GILLIGAN PAUL JOSEPH (US) | 2003-03-20 | — | — | US | disclosed |
| US-6521636-B1 | Treatment of psychiatric disorders and neurological diseases | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-18 | — | — | US | disclosed |
| US-6365589-B1 | FOR THERAPY OF PSYCHIATRIC DISORDERS AND NEUROLOGICAL DISEASES INCLUDING AFFECTIVE DISORDER, ANXIETY, DEPRESSION, HEADACHE, IRRITABLE BOWEL SYNDROME, POST-TRAUMATIC STRESS DISORDER, SUPRANUCLEAR PALSY, IMMUNE SUPPRESSION, ALZHEIMER'S DISEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023965-A1 | Imidazo-triazines as corticotropin releasing factor antagonists | CRH, CRHR1, CRHR2 | CNR2 163/4885CNR1 86/4885MAPT 3909/4885 |
| US-20030055059-A1 | For therapy of psychiatric disorders and neurological diseases including affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease | CRH, PCNP, CRHR1 | CNR2 60/4885CNR1 30/4885MAPT 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.